DEEP DIVE
⚖️ The Secondary Defect Is Why Your Flap Claims Get Denied

Most flap denials don't come from a bad repair. They come from a thin description of the secondary defect.

"Incised and carried over" is the phrase every payer already expects, and most surgeons know to include it. The harder problem sits one line down. Where exactly were the incisions placed to create the secondary defect, and what did that defect look like? That's the section reviewers read closely, and the section boilerplate tends to fill. A surgeon can describe a textbook repair, document every step, and still lose the payment, because the note proves the surgery happened without proving the procedure qualifies for the code billed. That gap, between a note that is clinically complete and one that is payment-complete, is where adjacent tissue transfer denials live.

Why the flap note is the only defense

Adjacent tissue transfer codes, CPT 14000–14302 (rotation flaps, advancement flaps, VY/Z/W-plasty, random island flaps), cover the repairs dermatologists reach for on large or awkward defects, often after Mohs. These sit a tier above the intermediate and complex closures we covered earlier, and they are among the few codes where the documentation has to carry the entire claim by itself.

The Medicare NCCI Policy Manual, Chapter III, Section H.1 bundles both the excision (11400–11646) and the repair (12001–13160) into the ATT code. Those component codes cannot be reported separately for the same lesion. So when an ATT claim gets denied, there is typically no fallback line to bill. The flap code is the whole payment, which means the flap note carries the whole claim. A denied excision or closure usually leaves you a separate code to rework; a denied flap usually leaves nothing but the appeal, which is why the note has to qualify the procedure the first time it is read.

What the manual actually says

The denials trace back to one sentence. Section H.3 of the same manual draws the line between a complex repair and a true tissue transfer:

"Extensively undermining of adjacent tissue to achieve closure of a wound or defect may constitute complex repair, not tissue transfer and rearrangement. Tissue transfer and rearrangement requires that adjacent tissue be incised and carried over to close a wound or defect."

The federal rule says ATT requires tissue that was incised and carried over. A note that describes undermining and closure, but never shows tissue being incised and moved across the defect, reads like a complex repair, not a flap. The code says one thing. The documentation describes another. The claim gets recategorized down, or denied outright.

That's the rule everyone enforces. Any payer following NCCI reads the note against the same Section H.3 language, which is why "incised and carried over" belongs in every ATT note regardless of who's paying. Where claims actually fail is one step past that phrase: the description of the secondary defect, the incisions that created it, and its shape and dimensions. That's the detail boilerplate skips and reviewers flag. UHC and Optum have been the most vocal here. Based on direct feedback Clarity's coding team is seeing on these claims, they're now asking for the secondary-defect incisions described specifically, and the common stand-in, "expected incisions were placed within the relaxed skin tension lines where possible," is not clearing review. In some cases they also want color photographs of the pre-op defect, the flap and secondary-defect incision lines, and the completed repair, alongside the written note. That's the early signal, not a UHC-only requirement. There's no reason to document a flap one way for one payer and another way for the next, so the smart move is to write to the strictest standard every time. One documentation standard, every payer.

The gap between a good note and a paid note

A surgeon documenting for the chart writes to prove the care was sound. A note written to get paid has to do that and clear the code's definitional bar at the same time. Most flap notes are clinically excellent and payment-incomplete, and the fix is usually a matter of language, not technique.

Take the standard incision line. "The area thus outlined was incised deep to the adipose tissue with a #15 scalpel blade" is clinically accurate and says nothing about whether the tissue moved. Add the four words the manual is looking for and it becomes "...incised deep to the adipose tissue with a #15 scalpel blade and carried over to cover the primary defect." Same surgery. The second version qualifies for the code.

The secondary defect is where boilerplate fails fastest, and where the strongest notes do their work. "Placing the expected incisions within the relaxed skin tension lines where possible" describes intent, not the procedure. What a clean note reads like is this: "Curvilinear incision, approximately 3cm in length, along the right nasolabial fold, extending from the ala of the nose to the oral commissure." Shape, dimension, anatomical landmarks, and orientation give the reviewer enough to picture the flap on the page. The first version asks them to take the surgery on faith, and reviewers paid to find reasons to deny rarely do.

Takeaways

  1. Describe the secondary defect like you're drawing it for the reviewer. For each incision that creates it, document shape, length and width, precise anatomical location, and relationship to landmarks ("3cm curvilinear incision along the right nasolabial fold"). Include the final defect size in square centimeters, counting both the primary and secondary defects. This is the section that decides most flap claims, and the one most likely to be thin.

  1. Put "incised and carried over" in every ATT note. Add it to the incision description so the note tracks the NCCI Chapter III, Section H.3 language word for word. This is the phrase that distinguishes a flap from a complex repair in the edit's eyes, and every payer following NCCI is reading for it.

  1. Treat photo documentation as standard, not appeal-only. Capture color images of the pre-op defect, the flap and secondary-defect incision lines, and the completed repair. Some payers, notably UHC and Optum, want these alongside the written note. Making them routine means you're covered everywhere, and you've closed the loop before a denial starts.

Bottom line: Write the note in the language the code requires, on the first pass, to one standard for every payer, so the documentation is built for the edit instead of for the appeal.

What did you think of today's edition?

Login or Subscribe to participate

UPCOMING EVENTS + REMINDERS
📆 Mark your calendars:

  1. CMS Doctors & Clinicians Preview Period closes (CY 2024 MIPS data) — June 11, 2026. Last chance to preview and request corrections to 2024 MIPS performance data before it posts publicly on Care Compare. CMS Spotlight & Announcements

  2. CMS-0062-P prior-auth proposed rule comment deadline — June 15, 2026. Comments close on the proposed rule to streamline electronic prior authorization for drugs across MA, Medicaid, CHIP, and Exchange plans, directly relevant to derm biologics and JAK inhibitors. Federal Register (CMS-0062-P)

  3. CAHPS for MIPS Survey registration closes — June 30, 2026. Final deadline for groups to register to administer the CAHPS for MIPS survey for the 2026 performance year. QPP Timeline & Deadlines

  4. HCPCS Level II Q3 2026 quarterly update takes effect — July 1, 2026. The next quarterly HCPCS file, including drug, biologic, and skin-substitute codes, becomes effective. CMS HCPCS Quarterly Update

  5. CMS Clinical Lab private-payer data reporting window — open through July 31, 2026. Applicable labs reporting January 1 to June 30, 2025 data submit during the May 1 to July 31 window, relevant to in-house dermatopathology. QPP / CMS Deadlines

Until next week,
The Practice Layer, powered by Clarity RCM

Built by the people who do this every day.

Clarity RCM manages revenue cycle for 200+ dermatology practices across 42 states. It's all we do. See how we work.

Reply

Avatar

or to participate

Keep Reading